Randomized Trialvery high evidence
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine·August 14, 2025·PMID 40544433
Why it mattersThis trial provides high-quality evidence for a novel dual agonist combination that achieves weight loss approaching that of bariatric surgery, expanding pharmacotherapy options for obesity management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled